RT Journal Article
SR Electronic
T1 Is Covid-19 seroprevalence different in health care workers as per their risk of exposure? A study from a tertiary care hospital in National Capital Region of India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.10.21251543
DO 10.1101/2021.02.10.21251543
A1 Sushila Kataria
A1 Rashmi Phogat
A1 Pooja Sharma
A1 Vikas Deswal
A1 Sazid Alam
A1 Manish Singh
A1 Kuldeep Kumar
A1 Vaibhav Gupta
A1 Padam Singh
A1 Rohit Dutt
A1 Smita Sarma
A1 Renu Saxena
A1 Naresh Trehan
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251543.abstract
AB Background SARS-CoV-2 infection has severely ravaged health systems, economic and social progress globally in 2020. Seroprevalence studies can provide relevant information on the target populations for vaccination. They are relevant not only in the community, but also for critical population subgroups such as nursing homes or health care facilities. They will assist in strategizing the vaccination policy especially since there is limited availability of the vaccine and vaccine hesitancyObjective To evaluate the seroprevalence in Health Care Workers (HCW) at our hospital and to identify parameters which may affect it.Methodology The Baseline profiling and seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was assessed among 3258 healthcare workers (HCWs) of Medanta-The Medicity, Gurugram, Haryana, India, as a part of an ongoing cohort study.The fully automated LIAISON® SARS-CoV-2 S1/S2 IgG test using the chemiluminescence immunoassay (CLIA) for the quantitative determination of anti-S1 and anti-S2 specific IgG antibodies to SARS-CoV-2 was used to test serum samples collected before the receipt of the vaccine. Seroprevalence was evaluated as per gender, age, association with previous Covid-19 diagnosis, use of supplements, and role in the hospital and type of exposure.Results Of the 3258 participants tested for IgG serology (S1 and S2 proteins) 46.2% (CI 44.4 – 47.9%) were positive (i.e. had an antibody titre more than 15 Au/ml). Higher seroprevalence was seen in the ‘others’ ie non clinical health care workers (including management, research personnel, pharmacists, technicians, general duty staff, housekeeping, security, food and beverage, and facility maintenance teams) (50.2 Au/ml) than that in clinical HCW (ie doctors and nurses)where it was significantly lower (41.4 Au/ml, p= 0.0001). Also, people with history of Covid-19 were found to have significantly higher antibody levels (p = 0.0001). Amongst the healthcare workers, doctors and nurses had higher relative risk of acquiring Covid-19 infection (RR = 1.21; 95% C.I.: 1.12 - 1.31).Conclusion Seroprevalence in healthcare workers at our hospital is high at 46.2%. It is higher in non-clinical HCW than in clinical HCW. The risk of acquiring Covid-19 infection was higher in clinical HCW and thus, this subgroup may benefit most from vaccination. History of Covid-19 may provide double the protection, in particular in those who had it recently.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2021/01/030582Funding StatementFunding support from an intramural grant of the Medanta Institute of Education and ResearchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medanta Institutional Review Board and Medanta Institutional Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the hospital